Hyrimoz FDA Approval History

Last updated by Judith Stewart, BPharm on May 27, 2025.

FDA Approved: Yes (First approved October 30, 2018)
Brand name: Hyrimoz
Generic name: adalimumab-adaz
Dosage form: Injection
Company: Sandoz Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, Uveitis

Hyrimoz (adalimumab-adaz) is an anti-TNF-α monoclonal antibody biosimilar/interchangeable to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

• Hyrimoz is indicated for the treatment of:
  - Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
  - Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
  - Psoriatic Arthritis: reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
  - Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS.
  - Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
  - Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adult patients.
  Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
  - Plaque Psoriasis (Ps): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
  - Hidradenitis Suppurativa (HS): treatment of moderate to severe hidradenitis suppurativa in adult patients.
  - Uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adults.
• Hyrimoz is approved in the following dosage forms:
  

  Product Presentation	Strength	Biosimilar / Interchangeable
  Pre-Filled Syringe	10 mg / 0.1 mL	Interchangeable
  Pre-Filled Syringe	10 mg / 0.2 mL	Interchangeable
  Pre-Filled Syringe	20 mg / 0.2 mL	Interchangeable
  Pre-Filled Syringe	20 mg / 0.4 mL	Interchangeable
  Pre-Filled Syringe	40 mg / 0.4 mL	Biosimilar
  Pre-Filled Syringe	40 mg / 0.8 mL	Interchangeable
  Pre-Filled Syringe	80 mg / 0.8 mL	Interchangeable
  Autoinjector	40 mg / 0.4 mL	Biosimilar
  Autoinjector	40 mg / 0.8 mL	Biosimilar
  Autoinjector	80 mg / 0.8 mL	Biosimilar

• Hyrimoz is administered via subcutaneous injection.
•  The FDA approval of Hyrimoz was based on analytical, nonclinical, pharmacokinetic and clinical data supporting biosimilarity to the reference product Humira. Safety and immunogenicity were also comparable.
•  Hyrimoz comes with a Boxed Warning alerting health care professionals and patients of the increased risk of serious infections and malignancies.
•  The most common reported side effects include infections (including upper respiratory, sinusitis), injection site reactions, headache, and rash.
•  Hyrimoz is the third FDA-approved adalimumab biosimilar.

Humira Biosimilars

Development timeline for Hyrimoz

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer